日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

USP14-mediated metabolic competition impairs CD8+ T cell immunosurveillance in hepatocellular carcinoma

USP14介导的代谢竞争会损害肝细胞癌中CD8+ T细胞的免疫监视功能。

Yuan, Yichuan; Niu, Yi; Huang, Zhenkun; Shi, Yunxing; Lin, Zhu; Zuo, Dinglan; Zhong, Chengrui; Li, Kai; Guan, Xin-Yuan; Yuan, Yunfei; Li, Binkui

Regulatory factor X1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by transcriptional regulation of BECN1.

调控因子 X1 通过转录调控 BECN1 促进索拉非尼诱导的肝细胞癌铁死亡

Yang Zhiwen, Yuan Yichuan, Niu Yi, Zuo Dinglan, Liu Wenwu, Li Kai, Shi Yunxing, Qiu Zhiyu, Li Keren, Lin Zhu, Zhong Chengrui, Huang Zhenkun, He Wei, Guan Xinyuan, Yuan Yunfei, Zeng Weian, Qiu Jiliang, Li Binkui

The triglyceride-glucose index associated with reduced risk of liver metastasis in pancreatic cancer

甘油三酯-葡萄糖指数与胰腺癌肝转移风险降低相关

Yi, Taijun; Lin, Zejin; Mai, Ziyan; Liang, Yongling; Zhong, Chengrui; Li, Xingyu; Wang, Wandi; Huang, Xiaoyue; Lin, Zeyu; Wan, Yunle; Li, Guolin

Risk factors, prognostic factors, and nomograms for liver metastasis in stage T(is)-T(2) colorectal cancer patients from a population-based study

基于人群研究的T(is)-T(2)期结直肠癌患者肝转移的危险因素、预后因素和列线图

Lin, Zejin; Lin, Zeyu; Yi, Taijun; Liang, Yongling; Mai, Ziyan; Li, Xingyu; Zhong, Chengrui; Wan, Yunle; Li, Guolin

A novel immune-metabolic prognostic model stratifies survival and personalizes therapy in hepatocellular carcinoma

新型免疫代谢预后模型可对肝细胞癌患者的生存期进行分层并实现个体化治疗

Lin, Zejin; Wang, Jiaheng; Li, Yiping; Yi, Taijun; Huang, Xiaoyue; Zhong, Chengrui; Chen, Zhiping; Lin, Zeyu

Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma

采用经动脉化疗栓塞联合肝动脉灌注化疗治疗初始不可切除的肝细胞癌,使其转化为可切除肿瘤。

Li, Binkui; Qiu, Jiliang; Zheng, Yun; Shi, Yunxing; Zou, Ruhai; He, Wei; Yuan, Yichuang; Zhang, Yuanping; Wang, Chenwei; Qiu, Zhiyu; Li, Kai; Zhong, Chengrui; Yuan, Yunfei